Real-World Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study - Summary - MDSpire
To evaluate the impact of hydroxychloroquine (HCQ) blood level monitoring on systemic lupus erythematosus (SLE) outcomes and to assess how kidney function and other factors influence HCQ dosing.
Approach:
Cohort Study: Data were collected from a prospective SLE cohort at the University of Wisconsin, including patients aged 18 and older on HCQ for at least three months, with random HCQ blood levels and SLE Disease Activity Index (SLEDAI-2K) assessments at follow-up visits.
Key Findings:
Patients with eGFR ≤75 mL/min/1.73m2 are at higher risk for supratherapeutic HCQ levels.
Female and Asian patients had significantly lower HCQ blood levels despite weight-based dosing.
Very low (<200 ng/mL) and subtherapeutic (200 to <750 ng/mL) HCQ levels predict higher odds of active SLE.
Maintaining therapeutic HCQ levels (750 to <1,150 ng/mL) is associated with significantly lower odds of active SLE.
Interpretation:
Routine HCQ blood level monitoring can guide optimal dosing, particularly in patients with chronic kidney disease or chronic transaminitis, and may improve SLE control.
Limitations:
The study primarily involved a single cohort from one institution, which may limit generalizability.
Random (non-trough) HCQ blood levels may not reflect the full pharmacokinetic profile.
The absence of longitudinal studies monitoring clinical effectiveness of HCQ blood level monitoring limits the generalizability of findings.
